TScan Therapeutics (TCRX) EBT (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly EBT of -$28.7 million for Q1 2026, up 22.49% year-over-year from -$23.4 million in Q1 2025, and up 9.98% quarter-over-quarter from -$31.8 million in Q4 2025.
TScan Therapeutics (TCRX) EBT (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported EBT for 7 consecutive years, with -$28.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 22.49% year-over-year to -$28.7 million; the TTM figure through Mar 2026 stood at -$133.2 million (up 8.32% YoY), while the FY2025 annual figure was -$219.9 million, down 52.08% from the prior year.
- EBT rose to -$28.7 million in Q1 2026 per TCRX's latest filing, from -$31.8 million in the prior quarter.
- Across five years, EBT topped out at -$15.1 million in Q2 2022 and bottomed at -$46.7 million in Q4 2024.
- Historically, EBT has averaged -$27.4 million across 5 years, with a median of -$28.7 million in 2026.
- Annual changes were most pronounced in 2022 — EBT jumped 54.13% — and 2024, when it tumbled 130.68%.
- TScan Therapeutics' EBT stood at -$19.5 million in 2022, then fell by 3.64% to -$20.3 million in 2023, then slumped by 130.68% to -$46.7 million in 2024, then soared by 31.86% to -$31.8 million in 2025, then advanced by 9.98% to -$28.7 million in 2026.
- Business Quant data shows TCRX's EBT at -$28.7 million in Q1 2026, -$31.8 million in Q4 2025, and -$35.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | TScan Therapeutics | 101.63 Mn | 101.63 Mn | - | -30.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.36 Mn |
| Mar 31, 2026 | -28.67 Mn |
| Dec 31, 2025 | -31.84 Mn |
| Sep 30, 2025 | -35.71 Mn |
| Jun 30, 2025 | -36.95 Mn |
| Mar 31, 2025 | -36.98 Mn |
| Dec 31, 2024 | -46.73 Mn |
| Sep 30, 2024 | -29.89 Mn |
| Jun 30, 2024 | -31.66 Mn |
| Mar 31, 2024 | -30.14 Mn |
| Dec 31, 2023 | -20.26 Mn |
| Sep 30, 2023 | -23.00 Mn |
| Jun 30, 2023 | -24.05 Mn |
| Mar 31, 2023 | -22.56 Mn |
| Dec 31, 2022 | -19.55 Mn |
| Sep 30, 2022 | -16.25 Mn |
| Jun 30, 2022 | -15.10 Mn |
| Mar 31, 2022 | -16.16 Mn |
| Dec 31, 2021 | -14.89 Mn |
| Sep 30, 2021 | -25.29 Mn |